The U.S. Food and Drug Administration (FDA) has launched a partnership with the Clinical Data Interchange Standards Consortium and Critical Path Institute to develop standardized definitions for individual diseases and the therapeutic approaches to treat them in an effort to transform the massive data streams from drug studies on specific diseases into usable information. Dubbed the Coalition for Accelerating Standards (CFAST), the initiative brings together clinical data experts from FDA and the pharmaceutical and information technology sectors to develop and maintain data standards. According to FDA’s Center for Drug Evaluation and Research Director Janet Woodcock, “We at the FDA are excited to be a member of this important partnership. We believe that CFAST will provide an important resource for drug development and research that will result in enhancements in the evaluation of safe and innovative therapies for the public.” See ExpressPharmaOnline, October 25, 2012.